epirubicin hydrochloride - Profile

What are the generic drug sources for epirubicin hydrochloride and what is the scope of freedom to operate?

Epirubicin hydrochloride is the generic ingredient in two branded drugs marketed by Pfizer Inc, Actavis Totowa, Cipla Ltd, Ebewe Pharma, Epic Pharma Llc, Fresenius Kabi Usa, Hikma, Hisun Pharm Hangzhou, Hospira, Impax Labs Inc, and Pharmobedient, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

Summary for epirubicin hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	11
NDAs:	15

US Patents and Regulatory Information for epirubicin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer Inc	ELLENCE	epirubicin hydrochloride	INJECTABLE;INJECTION	050778-001	Sep 15, 1999	AP	RX	Yes	Yes
Pfizer Inc	ELLENCE	epirubicin hydrochloride	INJECTABLE;INJECTION	050778-002	Sep 15, 1999	AP	RX	Yes	No
Actavis Totowa	EPIRUBICIN HYDROCHLORIDE	epirubicin hydrochloride	INJECTABLE;INJECTION	065445-001	Sep 18, 2008		DISCN	No	No
Actavis Totowa	EPIRUBICIN HYDROCHLORIDE	epirubicin hydrochloride	INJECTABLE;INJECTION	065445-002	Sep 18, 2008		DISCN	No	No

Investment Scenario and Patent/Regulatory Fundamentals for Epirubicin Hydrochloride (Epirubicin HCl)

Last updated: July 10, 2026

Epirubicin hydrochloride is an established oncology cytotoxic. Investment economics are driven by (1) how durable branded supply remains versus generic erosion, (2) whether any line-extension patents or formulation exclusivities extend useful market life in specific geographies, and (3) steady demand for breast cancer and gastric indications where epirubicin remains in standard regimens. In the US, investment upside is constrained by likely full patent extinction for the underlying active and the high probability of generic availability; the primary monetization vector is market share retention, tender positioning, and lifecycle management through formulations and packaging rather than new chemical entity IP.

What patents protect epirubicin hydrochloride and how strong is the patent estate?

Which types of patents typically exist for epirubicin HCl

For legacy chemotherapies like epirubicin, patent landscapes usually separate into:

• Core substance and early manufacturing process filings (generally long expired in major markets).
• Second-generation patents, including specific manufacturing controls, impurities, intermediates, and drug substance/polymorph-like characterizations (less common for classic small-molecule salts at this stage).
• Formulation and presentation patents (concentrations, container closure systems, stabilizers, lyophilized vs solution formats, infusion compatibility).
• Therapeutic regimen patents (method-of-use), often pursued by combination and dosing-strategy entities.

What is the practical IP strength today

Given epirubicin hydrochloride’s age and the standard-of-care status across multiple cancers, the practical IP strength in developed markets typically rests on:

• Local formulation/presentation patents that are jurisdiction-specific.
• Limited time left on any combination or regimen patents tied to specific partner drugs.
• Regulatory exclusivity that applies only to specific marketing authorizations and not the molecule itself.

Actionable implication for investors: treat epirubicin HCl as a “supply and reimbursement” investment, not an “IP-led growth” thesis, unless the target asset is a specific protected formulation in a named territory.

Patent estate mapping approach for diligence

A diligence-grade view should classify each patent by:

• Jurisdiction (US, EP, UK, CA, AU, JP, CN, IN, etc.)
• Claim category (compound, process, formulation, method-of-use)
• Expiration (max term and any patent term adjustments)
• Status (granted, pending, expired, litigated)
• Orange Book or equivalent listing (US) and linkage to specific FDA NDA/ANDA

When does epirubicin lose exclusivity and what are the likely expiration drivers?

US exclusivity reality: generic headwinds

For old cytotoxics, “lose exclusivity” usually occurs through one or more of these pathways:

• Expiration of composition-of-matter and related manufacturing/process patents.
• End of any regulatory data exclusivity (often not relevant to an old active).
• Termination of any formulation-specific exclusivity tied to a particular reference product.

Featured snippet answer: Epirubicin hydrochloride’s commercial exclusivity in the US is typically already exhausted for the active itself; remaining exclusivity, if any, tends to be tied to specific approved product presentation and/or narrow process/formulation claims.

European and emerging market timelines

In Europe and other jurisdictions, remaining exclusivity depends on:

• Whether a specific marketing authorization holder obtained later-life formulation patents.
• Local patent filing dates and whether they were granted and maintained.
• Conversion of patents into validated national rights.

Actionable implication: build country-level “market exclusivity calendars” rather than relying on molecule-level dates.

What is the Orange Book status of epirubicin hydrochloride in the US?

How Orange Book status usually looks for legacy cytotoxics

The Orange Book links patents to specific FDA-approved products. For epirubicin HCl, Orange Book listings, if present, frequently show:

• Patents already expired or close to expiry.
• A small set of formulation/packing-related patents for certain concentrations or container presentations.
• Multiple generic AB-rated equivalents across manufacturers.

Featured snippet answer: Orange Book patent listings for epirubicin HCl are usually not the gating factor for generic entry in the US for the molecule itself; entry risk is commonly driven by manufacturing, labeling, and supply chain rather than patent barriers.

Investment diligence checklist using Orange Book

• Identify the reference listed drug(s) (RLDs) for each concentration/form.
• Record each listed patent number and expiration date.
• Confirm which patents are “expired” vs “active” as of the latest Orange Book update.
• Map each active patent to the dosage form/container.

Which generic entry risks exist for epirubicin hydrochloride and what triggers Paragraph IV?

Paragraph IV likelihood

Paragraph IV challenges require an ANDA with a patent certification against listed patents for the RLD. For a mature active, Paragraph IV is typically more likely when:

• A formulation patent remains active in the Orange Book.
• A new reference product with protected presentation was launched more recently.
• A specific packaging or concentration has a narrower patent shelf that generic applicants can target.

What to model for a generic launch scenario

For investors evaluating a branded manufacturer or a licensee:

• Time to ANDA approval (tentative approval dates if discoverable).
• Launch timing relative to patent expiration and exclusivity windows.
• Expected price erosion (historically steep for sterile oncology injectables after generic normalization).
• Contract tender behavior: hospitals may switch within procurement cycles even before the full patent wall collapses.

Actionable implication: base revenue models on tender migration and gross-to-net compression, not on presumed lasting patent protection.

What formulation patents protect epirubicin hydrochloride (dosage form and container closure)?

Formulation/IP categories that matter for revenue

In oncology injectables, investors should focus on:

• Stability and shelf-life claims (temperature excursions, reconstitution/infusion stability).
• Compatibility with infusion systems (PVC, non-PVC tubing, and in-line filters where applicable).
• Container closure system claims (vials, stoppers, seals) tied to leachables/extractables controls.
• Concentration-specific presentations (for dosing accuracy in pediatrics/adults).

Commercial relevance

Formulation patents can delay direct competition for:

• Specific vial sizes used by oncology day units.
• Ready-to-dilute concentrations preferred by hospital pharmacy.
• Supply chain resilience (longer shelf-life supports fewer stockouts).

Investment takeaway: even with expired active-molecule IP, product-specific formulation patents can create short-term, geography-specific price protection.

What method-of-use patents exist for epirubicin hydrochloride in breast cancer or gastric cancer?

How method-of-use IP impacts commercial value

Method-of-use patents can affect:

• Off-label prescribing patterns if risk is credible and litigation is active.
• Combination regimen selection when a branded label supports usage and patents are asserted in litigation.

Practical risk profile

Method-of-use patents are often harder to enforce against routine clinical use for older chemotherapies unless:

• The patent claims are narrowly tied to a specific dosing schedule and partner regimen.
• Enforcement is supported by continuing clinical guideline relevance and strong label alignment.

Actionable implication: treat method-of-use patents as secondary to product lifecycle and supply economics unless there is active litigation or a recent combination NDA/label expansion.

How does epirubicin hydrochloride compare with doxorubicin in terms of competitive landscape and IP barriers?

Market substitution dynamics

Epirubicin is often selected over doxorubicin in certain breast and gastric regimens, but real-world substitution depends on:

• Local guidelines and reimbursement.
• Drug availability and procurement contracts.
• Clinician familiarity and toxicity management practices.

Investor-relevant comparison

• If competitors face fewer manufacturing constraints, procurement may shift quickly.
• If a particular supplier has better logistics (shelf-life, vial formats), it can win tenders even when prices are similar.

Actionable implication: competitive strategy should prioritize supply reliability, procurement terms, and manufacturing robustness.

What patent litigation affects epirubicin hydrochloride?

Typical litigation pattern for legacy oncology injectables

For an old active, litigation tends to be concentrated on:

• The small remaining formulation/presentation patent set.
• Disputes over Orange Book listing validity.
• Generic labels and process claims in ANDA disputes.

Investment diligence approach

• Build a docket timeline for each RLD/form.
• Record asserted patents, outcomes, and settlement dates.
• Track whether injunctions occurred or whether cases settled into “at-risk” launch windows.

What settlement agreements and launch timing matter for epirubicin HCl?

Why settlements drive realized revenue

When generic applicants settle, they often include:

• Date-certain launch
• Territory limitations
• Payment terms or supply commitments
• Agreement on design-around changes

Actionable implication: for investors, settlements are as important as expiration dates. A “paper expiry” can be irrelevant if a settlement delays entry or accelerates it.

What is the FDA regulatory status of epirubicin hydrochloride and what manufacturing/IP barriers exist?

Regulatory status drivers

For sterile injectables, manufacturing barriers include:

• Sterile fill-finish compliance and batch consistency.
• Endotoxin and particulate control.
• Impurity specifications and stability documentation.

Why regulatory readiness is a gating factor

Even when patents are weak or expired, generic launches still depend on:

• ANDA CMC readiness for the exact concentration and container.
• Analytical comparability for old cytotoxics.
• Stability data bridging and shelf-life acceptance by regulators.

Investment implication: a supplier with proven sterile manufacturing capability may win market share faster than a purely IP-motivated entrant.

Commercial fundamentals: demand durability, pricing behavior, and revenue exposure

Demand durability

Epirubicin is used in:

• Breast cancer (commonly as part of anthracycline-based combinations).
• Gastric cancer (historically used in combination regimens in many settings).

For an investor, demand durability is best modeled as:

• Regression on regimen prevalence (guidelines and payer coverage).
• Patient flow and line-of-therapy shifts.
• Hospital formulary stability and procurement cycle length.

Pricing behavior after generic normalization

Legacy injectables typically see:

• Rapid price compression after generic entries.
• Gross-to-net pressure from contracting, discounts, and rebates.
• Increased volatility from tender dynamics.

Actionable implication: treat epirubicin HCl like a margin-managed, volume-sensitive business, with upside tied to contract wins and supply continuity.

Revenue exposure mapping

A diligence-grade model separates exposure by:

• Concentration and vial size (dosing economics).
• Territory (US vs EU vs ROW tender structure).
• Hospital segment (academic oncology centers vs community networks).
• Mix between branded reference product and authorized generics.

Which companies supply epirubicin hydrochloride and how does competitive intensity affect valuation?

Competitive intensity framework

High competitive intensity for epirubicin usually means:

• Many approved generics and multiple tender-capable manufacturers.
• Lower pricing power for brands.
• Faster switching when supply constraints ease.

Valuation implication

• Earnings quality depends on throughput and conversion of contracts.
• Capex and sterility assurance become central to risk-adjusted returns.
• IP-backed premium pricing is rarely sustained unless a specific product presentation remains protected.

Key takeaways for investment decisioning

• Epirubicin hydrochloride is a mature oncology asset where value is primarily driven by supply execution, tender positioning, and sterile manufacturing performance rather than new IP.
• Remaining patent protection, when it exists, is usually product- and presentation-specific, not compound-level.
• In the US, Orange Book-linked barriers are typically not the main determinant of generic entry for the molecule itself; investors should focus on any active listed patents tied to exact RLD forms.
• Generic launch risk is best modeled through settlement and tender timing, not only expiration calendars.
• Regulatory and CMC readiness is a practical barrier that can slow entry even when patents are weak.

FAQs

1. What are the typical Orange Book patent categories listed for epirubicin hydrochloride products?
2. How do hospital tender cycles influence realized price erosion after epirubicin generic launches?
3. Which CMC factors most often determine whether an ANDA for an old sterile cytotoxic can launch on time?
4. How do settlements vs. patent expiration dates change the launch-risk profile for epirubicin products?
5. When comparing epirubicin and doxorubicin, what procurement and guideline factors drive real-world substitution?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. FDA. Paragraph IV certification and ANDA requirements (21 CFR framework and FDA guidance materials). FDA.
3. European Medicines Agency. EPARs and product lifecycle information for epirubicin-containing medicines. EMA.